AbbVie's Venetoclax Misses Key Goal in Phase 3 Study for Multiple Myeloma Patients
- Wednesday, October 16, 2024
The recent Phase 3 study conducted by AbbVie to evaluate the efficacy and safety of their cancer drug, venetoclax, in combination with dexamethasone has fallen short of its primary endpoint for certain patients with the blood cancer multiple myeloma.
AbbVie, a biopharmaceutical company based in North Chicago, Illinois, revealed that the combination treatment did not show a significant improvement in progression-free survival for patients with t(11;14)-positive relapsed or refractory multiple myeloma who had undergone two or more prior treatments.
Although the results were not statistically significant, AbbVie observed that patients who received the venetoclax-dexamethasone combination experienced a median progression-free survival of 9.9 months, compared to 5.8 months in patients treated with the pomalidomide-dexamethasone combination.
AbbVie is collaborating with Swiss drug giant Roche Holding on the development of venetoclax, which is marketed under the brand names Venclexta and Venclyxto. Currently, it holds approvals for the treatment of chronic lymphocytic leukemia and acute myeloid leukemia. In the United States, AbbVie and Roche's Genentech jointly market the drug, while AbbVie alone handles international marketing.
All Rights Reserved © 2024
Post a comment